Measuring human complement activation by HLA antibodies

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 3, 2006, Pages 368-373

  Watanabe, Jota ^a,b   Scornik, Juan C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; HLA ANTIBODY;

ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FLOW CYTOMETRY; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MEASUREMENT; SERUM; STANDARD; T LYMPHOCYTE; TARGET CELL; TRANSPLANTATION;

COMPLEMENT ACTIVATION; COMPLEMENT C3; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION;

EID: 33644971074     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation. 2000;70:887-895.
2. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3:1017-1023.
3. Feucht HE. Complement C4d in graft capillaries: the missing link in the recognition of humoral immunity. Am J Transplant. 2003;3:646-652.
4. Dong J, Pratt JR, Smith RAG, et al. Strategies for targeting complement inhibitors in ischemia/reperfusion injury. Mol Immunol. 1999;36:957-963.
5. Saadi S, Platt JL. Endothelial cell responses to complement activation. In: Volanakis JE, Frank MM, eds. The Human Complement System in Health and Disease. New York, NY: Marcel Dekker Inc; 1998:335-353.
6. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964;204:998-1000.
7. Spiller OB. Measurement of C3 fragment deposition on cells. In: Morgan BP, ed. Methods in Molecular Biology: Complement Methods and Protocols. Vol 150. Totowa, NJ: Humana Press Inc; 2000:131-137.
8. Arnold ML, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288-1296.
9. Fuller TC, Fuller AA, Golden M, Rodey GE. HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. Hum Immunol. 1997;56:94-105.
10. Kushihata F, Watanabe J, Mulder A, Claas F, Scornik JC. HLA antibodies and human complement activation. Role of IgC subclass, specificity and cytotoxic potential. Transplantation. 2004;78:995-1001.
11. Scornik JC, Salomon DR, Howard RJ, Pfaff WW. Evaluation of antibody synthesis in broadly sensitized patients. Transplantation. 1988;45:95-100.
12. Johnson RJ. Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance. Nephrol Dial Transplant. 1994; 9(suppl 2):36-45.
13. Baldwin WM III, Pruitt SK, Brauer RB, et al. Complement in organ transplantation: contributions to inflammation, injury and rejection. Transplantation. 1995;59:797-808.
14. Duquesnoy RJ, Marrari M. Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods. Arch Pathol Lab Med. 2003;127:149-156.